RENOIR Trial — RSVpreF Vaccine Efficacy over Two Seasons
Source: View publication →
The RENOIR phase 3 trial demonstrated that a single dose of the bivalent RSVpreF vaccine provides durable, significant efficacy against RSV-associated lower respiratory tract illness (LRTI) in adults aged 60 years and older over two consecutive RSV seasons.
Key Findings
Study Design
Study Limitations
Clinical Significance
This study provides definitive evidence supporting the use of the bivalent RSVpreF vaccine in older adults, establishing it as a reliable tool to reduce the significant burden of morbidity associated with RSV, particularly for moderate-to-severe lower respiratory tract illness.
Historical Context
RSV vaccine development faced a major setback in the 1960s when a formalin-inactivated vaccine caused enhanced respiratory disease in vaccinated children. The development of vaccines targeting the stabilized 'prefusion' (preF) conformation of the RSV F glycoprotein—the critical target for neutralizing antibodies—has been a breakthrough, leading to the success of RENOIR and the subsequent regulatory approval of RSVpreF (Abrysvo).
Guided Discussion
High-yield insights from every perspective
What is the structural significance of targeting the 'pre-fusion' (preF) conformation of the RSV F protein in this vaccine, and how does this mechanism overcome the limitations of previous vaccine attempts?
Key Response
The RSV F protein undergoes a massive conformational change from pre-fusion to post-fusion to facilitate viral entry. The pre-fusion state contains highly potent neutralizing epitopes (specifically Site Ø) that are lost in the post-fusion state. Earlier vaccine attempts using formalin-inactivated virus or post-fusion proteins failed to induce high-quality neutralizing antibodies; by stabilizing the protein in the preF state, the vaccine induces a more robust and protective immune response suitable for the immunosenescent systems of older adults.
Based on the RENOIR trial findings, how should you counsel an 80-year-old patient regarding the timing of their RSVpreF vaccination if they already received a dose at the beginning of the previous RSV season?
Key Response
The RENOIR trial demonstrated that a single dose of the RSVpreF vaccine maintains significant efficacy (approx. 78% for LRTI with 3+ symptoms) through the end of a second RSV season. Therefore, current data do not support the need for an annual booster. You should counsel the patient that their initial dose remains protective and that they do not require another shot for the current season.
In the context of the bivalent nature of the RSVpreF vaccine used in RENOIR, how should we interpret the efficacy results against RSV A versus RSV B subgroups over the two-season period, and what are the implications for potential antigenic drift?
Key Response
The vaccine is bivalent, containing stabilized preF proteins from both RSV A and B subgroups. The trial showed consistent efficacy across both subgroups. This is critical because RSV subgroups often alternate in dominance between seasons. While significant antigenic drift in RSV is slower than in influenza, the durability of bivalent protection suggests that the vaccine provides a broad enough immune footprint to cover current circulating diversity, though long-term molecular surveillance remains necessary to detect escape mutants.
The RENOIR trial reports sustained efficacy over two seasons, but how do these results influence your clinical approach to the 'shared clinical decision-making' framework for patients with significant cardiovascular or pulmonary frailty who were underrepresented in the trial cohort?
Key Response
The trial shows the vaccine is effective and durable, which supports its use in high-risk groups. However, because Phase 3 trials often exclude the most frail elderly (e.g., those in long-term care or with end-stage COPD), the 'shared clinical decision-making' allows the clinician to weigh the high efficacy against the individual's specific risk of severe RSV complications versus the rare risk of inflammatory neurologic events (like GBS) observed in broader post-marketing data. The two-season durability increases the 'value' of the single-dose intervention in this framework.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Critique the use of 'RSV-associated LRTI with 3 or more symptoms' as a primary endpoint in Season 2 of the RENOIR trial. How does this threshold choice affect the statistical power and the reported Vaccine Efficacy (VE) compared to a more inclusive endpoint (e.g., 2 or more symptoms)?
Key Response
Increasing the symptom threshold (from 2+ to 3+) typically increases the specificity of the case definition at the cost of sensitivity. Statistically, this often results in a higher point estimate for Vaccine Efficacy because the vaccine is generally more effective at preventing severe disease than mild disease. However, it reduces the total number of events, which can widen the confidence intervals. Using the 3+ symptom endpoint allows for a more 'impressive' VE figure but may underestimate the total burden of RSV-related morbidity prevented by the vaccine.
As a reviewer, how would you evaluate the impact of the 'depletion of susceptibles' bias on the Season 2 efficacy estimates in the RENOIR trial, given that the study was conducted during the fluctuating epidemiology of the COVID-19 pandemic?
Key Response
Depletion of susceptibles occurs if the vaccine-protected group and the placebo group are no longer comparable at the start of Season 2 because many in the placebo group already gained natural immunity from Season 1 infections. Furthermore, COVID-19 mitigations (masking, distancing) suppressed RSV circulation in some regions. A rigorous review would require an analysis of whether the attack rates in Season 1 were high enough to skew the Season 2 denominator and whether the geographical distribution of cases remained balanced between arms over both years.
The 2023 ACIP recommendations for RSV vaccination in adults 60+ utilize a 'shared clinical decision-making' (Category B) approach. How do the RENOIR durability data through Season 2 specifically challenge or support a transition to a universal (Category A) recommendation in future updates?
Key Response
The demonstration of two-season durability significantly improves the cost-effectiveness profile of the vaccine, a key factor for ACIP in moving from 'shared decision-making' to a 'universal recommendation.' However, current guidelines (e.g., CDC/ACIP) remain cautious due to the limited absolute number of severe cases in the trial and the ongoing need for more robust safety data regarding rare adverse events like Guillain-Barré Syndrome. The RENOIR data supports the 'long-term benefit' side of the ledger, but most committees require more 'real-world' effectiveness data before removing the shared decision-making requirement.
Clinical Landscape
Noteworthy Related Trials
APEX Trial
Tested
RSVpreF vaccine (Abrysvo)
Population
Pregnant women
Comparator
Placebo
Endpoint
Medically attended RSV-associated lower respiratory tract illness
GSK AReSVi-006 Trial
Tested
RSVPreF3 OA vaccine
Population
Adults 60 years of age or older
Comparator
Placebo
Endpoint
RSV-related lower respiratory tract disease
VICTOR Trial
Tested
mRNA-1345 RSV vaccine
Population
Adults 60 years of age or older
Comparator
Placebo
Endpoint
RSV-associated lower respiratory tract disease
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis